CMHC Masterclass On Demand: Addressing Cardiometabolic Risk in Children and Adolescents - Challenges and Solutions
The rapid rise of cardiometabolic disease and risk factors in children and adolescents is a huge cause of concern now and in the future. According to the CDC, close to 14 million children and adolescents aged 2-19 years have obesity in the US, with the prevalence increasing by more than 33% in the last two decades. In turn, this increase in obesity is strongly associated with increased rates of hypertension, dyslipidemia, type 2 diabetes, as well as increased overall cardiovascular risk in the pediatric population.
The roots of cardiometabolic disease begin in childhood, but clinicians may not feel confident about screening, diagnosing and treating these conditions early on. This stems from a host of multi-factorial issues, including a lack of solid evidence-base for this population compared to adults, limited treatment options, and lack of familiarity with current guideline recommendations and evidence. Addressing the full spectrum of cardiometabolic disease and risk in this population is of paramount importance.
These topics will be the focus of this two-day live CMHC Masterclass meeting, which will bring together leading experts that will cover practical strategies to improve the diagnosis and treatment of cardiometabolic disease and risk in pediatric patients.
The Cardiometabolic Health Congress (CMHC) is designed for US-based healthcare professionals, including endocrinologists, pediatricians, diabetologists, primary care physicians, cardiologists, lipidologists, and as well as nurses, nurse practitioners, and pharmacists.
After completing this activity, the participant should be better able to:
- Utilize screening and diagnostic tools to effectively identify and diagnose obesity, hypertension, and dyslipidemia in the pediatric population
- Initiate adequate and personalized lifestyle modifications in consultation with patients and their families to effectively address obesity and MetS in children and adolescents
- Interpret the efficacy and safety of treatment options for the management of complex pediatric patients with obesity, hypertension, dyslipidemia, type 2 diabetes, or obesity-related target-organ damage
- Develop comprehensive and individualized treatment plans for pediatric patients with cardiometabolic disease or cardiometabolic risk based on efficacy and safety of current, new, and emerging pharmacotherapies, benefits of lifestyle modifications, and patient profiles and preferences to optimize outcomes
Elaine M. Urbina, MD, MS (Chair)
Aaron S. Kelly, PhD
Carissa M. Baker-Smith, MD MPH MS
Joshua Samuels, MD, MPH
Stephen R. Daniels, MD, PhD
Jessica G. Woo, MHSA, PhD
Sarah De Ferranti, MD, MPH
Stavra Xanthakos, MD, MS
ESTIMATED TIME TO COMPLETE ACTIVITY
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 6 contact hour(s) (0.6 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2673-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 6 CPEUs for dieticians.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
A full listing of faculty disclosures can be downloaded here
Planners and Managers
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period April 6, 2021 through April 6, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 6.00 ACPE Pharmacy
- 6.00 AMA PRA Category 1 Credit™
- 6.00 ANCC
- 6.00 CDE
- 6.00 Participation
There are no registration fees for this activity. Please enroll and proceed with the course instructions.
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.